Medicus Pharma (MDCX) Competitors $2.93 -0.09 (-2.98%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MDCX vs. ENTA, LFVN, CCCC, ACOG, LYEL, IMRX, MOLN, LIMN, GLSI, and NKTXShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Enanta Pharmaceuticals (ENTA), Lifevantage (LFVN), C4 Therapeutics (CCCC), Alpha Cognition (ACOG), Lyell Immunopharma (LYEL), Immuneering (IMRX), Molecular Partners (MOLN), Liminatus Pharma (LIMN), Greenwich LifeSciences (GLSI), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. Medicus Pharma vs. Its Competitors Enanta Pharmaceuticals Lifevantage C4 Therapeutics Alpha Cognition Lyell Immunopharma Immuneering Molecular Partners Liminatus Pharma Greenwich LifeSciences Nkarta Enanta Pharmaceuticals (NASDAQ:ENTA) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Does the media prefer ENTA or MDCX? In the previous week, Medicus Pharma had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 6 mentions for Medicus Pharma and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.45 beat Medicus Pharma's score of 0.39 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medicus Pharma 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ENTA or MDCX? Enanta Pharmaceuticals currently has a consensus price target of $18.00, indicating a potential upside of 143.24%. Medicus Pharma has a consensus price target of $23.50, indicating a potential upside of 702.05%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Do institutionals & insiders believe in ENTA or MDCX? 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 13.9% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 11.2% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is ENTA or MDCX more profitable? Medicus Pharma has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -149.57%. Enanta Pharmaceuticals' return on equity of -79.83% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-149.57% -79.83% -26.65% Medicus Pharma N/A -380.03%-224.22% Which has stronger earnings and valuation, ENTA or MDCX? Medicus Pharma has lower revenue, but higher earnings than Enanta Pharmaceuticals. Medicus Pharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$67.64M2.34-$116.04M-$4.54-1.63Medicus PharmaN/AN/A-$11.16M-$1.16-2.53 SummaryEnanta Pharmaceuticals beats Medicus Pharma on 8 of the 15 factors compared between the two stocks. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.99M$3.03B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-2.5321.1828.1120.03Price / SalesN/A339.44461.57200.15Price / CashN/A43.2336.5559.01Price / Book10.108.368.655.90Net Income-$11.16M-$55.19M$3.25B$258.66M7 Day Performance-5.79%5.89%4.20%2.23%1 Month Performance7.33%17.63%10.82%12.76%1 Year PerformanceN/A5.09%34.70%19.36% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus Pharma2.3288 of 5 stars$2.93-3.0%$23.50+702.0%N/A$40.99MN/A-2.53N/AUpcoming EarningsENTAEnanta Pharmaceuticals3.931 of 5 stars$7.73+0.8%$18.00+132.9%-51.1%$163.96M$67.64M-1.70160Positive NewsLFVNLifevantage4.2567 of 5 stars$13.86+6.9%$30.50+120.1%+101.7%$163.27M$200.16M20.09260Positive NewsGap DownCCCCC4 Therapeutics2.8704 of 5 stars$2.42+9.0%$12.00+395.9%-61.4%$157.64M$35.58M-1.65150Upcoming EarningsACOGAlpha Cognition1.7311 of 5 stars$9.99+1.9%$20.00+100.2%N/A$156.99MN/A-8.32N/ALYELLyell Immunopharma2.5117 of 5 stars$10.99+6.9%$15.00+36.5%-67.7%$152.23M$60K-0.44270News CoverageGap UpIMRXImmuneering3.1424 of 5 stars$4.10-2.8%$13.25+223.2%+247.8%$151.86M$320K-2.0960MOLNMolecular Partners2.5708 of 5 stars$3.89+4.3%$12.00+208.5%-38.4%$150.67M$5.65M-2.03180News CoverageGap UpLIMNLiminatus PharmaN/A$6.47+11.9%N/AN/A$150.37MN/A0.00N/ANews CoverageGap DownHigh Trading VolumeGLSIGreenwich LifeSciences2.2011 of 5 stars$11.49+3.1%$39.00+239.4%-26.1%$148.92MN/A-9.123NKTXNkarta1.7718 of 5 stars$2.23+7.2%$14.33+542.8%-67.8%$147.59MN/A-1.48140 Related Companies and Tools Related Companies Enanta Pharmaceuticals Alternatives Lifevantage Alternatives C4 Therapeutics Alternatives Alpha Cognition Alternatives Lyell Immunopharma Alternatives Immuneering Alternatives Molecular Partners Alternatives Liminatus Pharma Alternatives Greenwich LifeSciences Alternatives Nkarta Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDCX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDCX Stock Alerts